Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Active Psoriatic Arthritis (PsA)
A Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab in the Treatment of Subjects With Active Psoriatic Arthritis
Sponsor: Janssen Research & Development, LLC
This PHASE2 trial investigates Psoriatic Arthritis and is currently completed. Janssen Research & Development, LLC leads this study, which shows 11 recorded versions since 2015 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Mar 2025 — Sep 2025 [monthly]
Completed PHASE2
-
Sep 2024 — Mar 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
▶ Show 6 earlier versions
-
Nov 2020 — Jan 2021 [monthly]
Completed PHASE2
-
Apr 2020 — Nov 2020 [monthly]
Completed PHASE2
-
Jun 2018 — Apr 2020 [monthly]
Completed PHASE2
-
May 2017 — Jun 2018 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Feb 2017 — May 2017 [monthly]
Active Not Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE2
First recorded
Mar 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Janssen Research & Development, LLC
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Arlington, United States , Barcelona, Spain , Barrie, Canada , Bataysk, Russia , Berlin, Germany , Bialystok, Poland , Boston, United States , Bucharest, Romania , Clearwater, United States , Cologne, Germany and 31 more locations